期刊
NATURE COMMUNICATIONS
卷 10, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-019-09068-2
关键词
-
资金
- NIH Breast SPORE grant [P50 CA098131]
- Vanderbilt-Ingram Cancer Center Support grant [P30 CA68485]
- Susan G. Komen for the Cure Breast Cancer Foundation [SAC100013]
- Breast Cancer Research Foundation
- Conquer Cancer Foundation ASCO Young Investigator Award [8364]
- Susan G. Komen Postdoctoral Fellowship [PDF15329319]
- Vanderbilt Clinical Oncology Research Career Development Program [2K12CA090625-17]
- NCI Research Specialist Award [R50 CA211206]
- AIRC under MFAG [21505]
Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resistant to fulvestrant +/- ribociclib or palbociclib. This resistance was abrogated by treatment with the FGFR tyrosine kinase inhibitor (TKI) lucitanib. Addition of the FGFR TKI erdafitinib to palbociclib/fulvestrant induced complete responses of FGFR1-amplified/ER+ patient-derived-xenografts. Next generation sequencing of circulating tumor DNA (ctDNA) in 34 patients after progression on CDK4/6 inhibitors identified FGFR1/2 amplification or activating mutations in 14/34 (41%) post-progression specimens. Finally, ctDNA from patients enrolled in MONALEESA-2, the registration trial of ribociclib, showed that patients with FGFR1 amplification exhibited a shorter progression-free survival compared to patients with wild type FGFR1. Thus, we propose breast cancers with FGFR pathway alterations should be considered for trials using combinations of ER, CDK4/6 and FGFR antagonists.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据